Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Suzanne "Sue" Sisley MD
Study ID
NCT07275970
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Psychedelic — DRUG
    Organic Whole Psilocybin-Containing Mushrooms

Study Details

This study will examine the safety and preliminary efficacy of psilocybin mushrooms to treat adults with PTSD. Up to 24 participants will take part in this study. Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.

Key Dates

Start date
Feb 9, 2026
Status verified
Jan 2026
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 30mg of psilocybin administered orally in a single dosing session

Primary Outcome Measure

Number/Incidence of adverse events (AEs), and serious adverse events (SAEs) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. [ Time Frame: From dosing to 3-month follow-up ]

Locations (1)

FacilityCityStateZIPSite coordinators
Scottsdale Research InstituteScottsdaleArizona85022
Sue Sisley, MD
[email protected]
(480) 326-6023
Suzanne (Sue) Sisley, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Scottsdale, AZ

By condition
PTSD (post-traumatic stress disorder)
By specialty
PsychiatryMental healthBehavioral health
By research site
Scottsdale Research Institute· Scottsdale, AZ

Related Studies